Tag: PhagoDAIR
Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections on prostheses caused by Staphylococcus aureus – 2022-11-29 at 18:00
Nantes, November 29, 2022 – 6 p.m. CET – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated…
Pherecydes Pharma: receives the positive opinion of the Committee for the Protection of Persons to initiate the PhagoDAIR study
Pherecydes Pharma receives the positive opinion of the Committee for the Protection of People to initiate the PhagoDAIR study PhagoDAIR is a…
Pherecydes: green light from ANSM for the PhagoDAIR study
(CercleFinance.com) – Pherecydes Pharma announces that it has obtained authorization from the French ANSM to carry out a phase I / II clinical study, PhagoDAIR, in the treatment of osteoarticular…